Business
Trump Tariffs Likely To Result In US GDP Go Down By 40-50 Bps: Report
Last Updated:
The US inflation is expected to stay above the 2 per cent target through 2026, driven by supply-side effects of tariffs and exchange rate movement, report said
The US decision to impose steep tariffs on Indian goods is set to weigh on the American economy by stoking inflationary pressures and slowing growth, the SBI said in its report. (AI-generated Photo)
As Indian exporters brace for the impact after additional 25 per cent US tariffs on key goods came into effect on Wednesday, reports said that Trump tariffs are likely to affect the US GDP by 40-50 bps by triggering inflationary pressures.
The US inflation is expected to stay above the 2 per cent target through 2026, driven by supply-side effects of tariffs and exchange rate movement, according to a report by SBI Research.
“The US is beginning to show signs of renewed inflationary pressure, driven by the pass-through effects of recent tariffs and a weaker dollar – particularly in import-sensitive sectors such as electronics, autos, and consumer durables,” the report mentioned.
The US decision to impose steep tariffs on Indian goods is set to weigh on the American economy by stoking inflationary pressures and slowing growth, the SBI said in its report.
“We believe that US tariffs is likely to affect US GDP by 40-50 bps and higher input cost inflation,” it added.
Addressing the Fed’s annual conference in Jackson Hole in the US, Federal Reserve Chair Jerome Powell is trying to balance rising prices and risks in a fragile job market. He said the effects of higher tariffs on prices are “now clearly visible”.
US wholesale prices jumped nearly 1 per cent in July – the fastest increase in over three years – as tariff war resulted into rising costs. The Producer Price Index rose 3.3 per cent year-on-year, with services, processed goods, and tariff-heavy imports like furniture and apparel seeing sharp price hikes.
Economists warn that unless tariffs are rolled back, families in the US will face more pressure on their budgets.
Earlier, the Department of Homeland Security (DHS) circulated a draft notification that it was imposing on Wednesday (US time) an additional 25 per cent tariff on India to address “threats to the United States by the Government of the Russian Federation”.
That is to be on top of the 25 per cent announced earlier, with exemptions for some items like electronics and pharmaceuticals.
(This story has not been edited by News18 staff and is published from a syndicated news agency feed – IANS)
Saurabh Verma covers general, national and international day-to-day news for News18.com as a Senior Sub-editor. He keenly observes politics. You can follow him on Twitter –twitter.com/saurabhkverma19
Saurabh Verma covers general, national and international day-to-day news for News18.com as a Senior Sub-editor. He keenly observes politics. You can follow him on Twitter –twitter.com/saurabhkverma19
Read More
Business
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.
Mike Blake | Reuters
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.
The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs.
Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes.
Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients.
Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx.
But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval.
That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly.
“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement.
Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.
With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024.
It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound.
Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic.
The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment.
Business
OBR chairman resigns over Budget leak
The chairman of the Office for Budget Responsibility (OBR) has resigned over the early publication of the watchdog’s forecasts.
Richard Hughes said he was resigning to allow the OBR to “quickly move on from this regrettable incident”.
His resignation follows publication of a report that described the leak as “the worst failure in the 15-year history of the OBR” and strongly criticised the watchdog’s processes for protecting sensitive information.
In a letter to the Chancellor and the chairwoman of the Commons Treasury Committee, Mr Hughes said he took “full responsibility” for “the shortcomings identified in the report”.
He said: “By implementing the recommendations in this report, I am certain the OBR can quickly regain and restore the confidence and esteem that it has earned through 15 years of rigorous, independent economic analysis.”
Mr Hughes has served as chairman of the OBR since 2020 and was reappointed to the job for a second five-year term in July this year.
Speaking in the Commons as the news of the resignation broke, Chief Secretary to the Treasury James Murray offered the Government’s thanks to Mr Hughes “for his dedication to public service”.
Later, the Chancellor herself offered her thanks for Mr Hughes’ “many years of public service”, adding: “This Government is committed to protecting the independence of the OBR and the integrity of our fiscal framework and institutions.”
Conservative leader Kemi Badenoch accused the Chancellor of using Mr Hughes as a “human shield” and called on Rachel Reeves to resign.
Liberal Democrat Treasury spokeswoman Daisy Cooper said Mr Hughes was “a dedicated public servant” who had “rightly taken responsibility for a failure on his watch”, adding the OBR needed to learn from its “catastrophic error”.
Treasury Committee chairwoman Dame Meg Hillier also thanked Mr Hughes, saying: “I commend his decision to take full responsibility for the incident and I wish him well for the future.”
The Treasury said it would begin the process of finding a replacement for Mr Hughes “in the coming weeks”.
The OBR launched an investigation after official forecasts were uploaded to the watchdog’s website, releasing details of the Budget almost an hour early.
In a report published on Monday, the OBR said the leak had been “seriously disruptive to the Chancellor, who had every right to expect that the (forecasts) would not be publicly available until she sat down at the end of her Budget speech”.
Noting Mr Hughes had already “rightly” apologised for the leak, the report said it was “not a case of intentional leakage” or a matter of pressing publish too early.
The OBR said it was caused by two errors linked to the WordPress publishing site it used.
The report into the incident said that, while it knew web addresses for its files follow a pattern, it assumed “the protections provided” by WordPress “would ensure it could not be accessed”.
But two configuration errors were the technical causes of the premature access.
The forecast for the last spring statement in March was also “accessed prematurely” on one occasion, the report noted, but concluded that no activity appeared to have been taken as a result and the most likely explanation is “benign”.
The report recommended a review of the watchdog’s processes for publishing such documents.
“To rebuild trust, the leadership of the OBR must take immediate steps to change completely the publication arrangements for the two important and time-sensitive documents containing the results of its biannual forecasts that it publishes in a normal year, and review arrangements for all other publications,” the report said.
One option would be for the watchdog to use the Government’s digital architecture but publish when it wants.
Another would be to have the Treasury publish the forecasts for the Budget and spring statement, but this would only work if safeguards for “real and perceived independence” could be put in place.
There may need to be an interim solution, the report noted, but said new arrangements must be in place in time for the next statement in spring 2026.
Business
OGRA Announces LPG Price Increase for December – SUCH TV
The Oil and Gas Regulatory Authority (OGRA) has approved a fresh increase in the price of liquefied petroleum gas (LPG), raising the cost for both domestic consumers and commercial users.
According to the notification issued, the LPG price has been increased by Rs7.39 per kilogram, setting the new rate at Rs209 per kg for December. As a result, the price of a domestic LPG cylinder has risen by Rs87.21, bringing the new price to Rs2,466.10.
In November, the price of LPG stood at Rs201 per kg, while the domestic cylinder was priced at Rs2,378.89.
The latest price hike is expected to put additional pressure on households already grappling with rising living costs nationwide.
-
Sports1 week agoWATCH: Ronaldo scores spectacular bicycle kick
-
Entertainment1 week agoWelcome to Derry’ episode 5 delivers shocking twist
-
Politics1 week agoWashington and Kyiv Stress Any Peace Deal Must Fully Respect Ukraine’s Sovereignty
-
Business1 week agoKey economic data and trends that will shape Rachel Reeves’ Budget
-
Politics1 week ago53,000 Sikhs vote in Ottawa Khalistan Referendum amid Carney-Modi trade talks scrutiny
-
Tech6 days agoWake Up—the Best Black Friday Mattress Sales Are Here
-
Fashion1 week agoCanada’s Lululemon unveils team Canada kit for Milano Cortina 2026
-
Tech1 day agoGet Your Steps In From Your Home Office With This Walking Pad—On Sale This Week
